A courier company is an unexpected place to begin the story of Paul Bresge. Industrial tools make an equally unlikely second stop. Yet both belong on the route to Ray Therapeutics, the company he co-founded in 2021. By then, Bresge had spent decades in operating roles and helped negotiate an international licensing agreement at jCyte. He was starting another business with considerable practice at the parts of business that rarely make a photograph.
Consider the contrast in scale. Ray began with a $6 million seed financing backed by 4BIO Capital. In April 2026, it announced a $125 million Series B led by Janus Henderson Investors. Between those announcements lies the work of assembling an organization, finding partners and persuading experienced people to commit their time. The round number is easy to remember. The assembled company is what has to keep working on Monday.
A résumé with several addresses
Bresge’s working life began well before the startup chapters. In May 1988, he became director of operations at Pharmasol. His next documented move took him to Blizzard in April 1992 as executive vice-president. In August 1998, he became chairman of ITC, an industrial tool company. By March 2003, he was Blizzard’s president and CEO. Manufacturing, deliveries and tools: a rather practical collection of nouns.
The jobs put operations near the center of his career. Their variety is also a useful corrective to the assumption that a founder’s earlier life must resemble the company he eventually starts. Bresge had a BA from York University and experience running businesses across sectors. When he entered a new field, he brought that operating background into conversations with specialists whose knowledge came from elsewhere.
His route offers a less tidy account of experience than the familiar ladder of progressively grander titles in one industry. Responsibilities accumulated across different organizations. Later, at Ray, his role would involve coordinating people with distinct expertise again. The connection is visible in the work: deciding whom to bring together, how to support them and which outside relationships could help an organization advance.
The years before the title
The jCyte chapter took shape through a long association. In February 2011, Bresge became advisory board chair and acting CEO. His appointment as CEO followed in August 2016. Those dates give the story some welcome texture. Before the executive title became settled, there were years of involvement with the company and its founders, Henry Klassen and Jing Yang.
For Bresge, entering the field involved reading research and bringing knowledgeable people into the evaluation. That willingness to ask for expertise matters in an operator’s story. A company founder can recognize an opportunity while still needing other people to judge its technical foundations. Bresge’s account includes that division of labor, with experienced evaluators helping him consider the work that interested him.
By 2020, he was leading jCyte into a substantial international partnership. In discussing the agreement, he credited the founders, colleagues and institutional supporters who had helped the company reach it. “Our team has worked hard together over many years,” he said. The sentence contains little theater. It gives the achievement a timescale, and gives the work more than one author.
A deal with three numbers
On May 8, 2020, jCyte announced its licensing and commercialization agreement with Santen. The stated value was up to $252 million, with royalties separate. The agreement covered markets outside the United States, including Europe and Asia. It connected a smaller company with an established international partner and the infrastructure that partner could bring to the relationship.
The financial structure deserves its own line of sight: $50 million in upfront cash, $12 million in a convertible note and up to $190 million in potential milestone payments. Those components describe different commitments. The largest was conditional. Keeping them separate preserves what Bresge and his colleagues had accomplished without turning a negotiated set of future possibilities into cash already received.
Up to $252 million in total, plus separate royalties.
Such details can seem less glamorous than the headline, which is their considerable charm. They show the machinery of a deal: immediate resources, a financing instrument and payments tied to later events. For an executive whose career had already passed through operating businesses, the agreement added another kind of organizational task. A partnership needed to be built around what each side could contribute over time.
Choosing who gets a seat
Bresge left jCyte at the end of 2020. A new venture followed in 2021: Ray Therapeutics. A contemporary corporate filing dates his co-founder role to February and his CEO role to June. Starting again meant returning to early decisions about capital and colleagues, with the experience of a previous company now part of the discussion.
One of those discussions was with Dmitry Kuzmin of 4BIO Capital. Bresge described conducting his own due diligence before Ray’s launch and finding that the investor’s questions about the science and market resembled his. This was a relationship in which both sides were evaluating the fit. Bresge wanted relevant knowledge at the table as well as funding.
“Once I had an introduction to Dima, I knew 4BIO was absolutely the right investor for us.”
Paul Bresge, on Dmitry Kuzmin
4BIO backed the $6 million seed round. Its existing experience in the field gave Bresge a reason to value Kuzmin’s participation beyond the initial check. For anyone building a company, this is the intimate side of institutional financing: selecting people who will be present for complicated decisions long after a funding announcement has disappeared from the news feed.
The returning names
In May 2023, Ray announced a $100 million Series A led by Novo Holdings. The participating investors included Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund and 4BIO. For Bresge, this brought a broader group into the company’s financing history. The seed investor remained involved as the capital requirements and circle of backers expanded.
The April 2026 Series B added another set of names. Janus Henderson led the $125 million round, with new investors Adage Capital Management, Franklin Templeton, Invus and Marshall Wace. All six investors named in the earlier Series A group participated again. Their return gives the financing sequence continuity as well as growth.
Bresge’s role sits within that network of repeated and new commitments. A founder remains a recognizable face while the organization acquires more participants, obligations and expertise. The financing history makes that expansion concrete. Ray’s backers now span specialist venture firms and larger investment organizations, each joining a company with an existing management team and board.
Hiring for the next chapter
Money also brings the question of who will manage the next stage. In September 2024, Ray appointed Chris Whitmore as chief financial officer. His background included early companies and public businesses, capital raising and strategic collaborations. Bresge welcomed his experience leading teams across private and public settings. The appointment gave the executive group a colleague whose career centered on financial and operational responsibilities.
In May 2026, Ray added Vikas Sinha to its board and named him chair of the audit committee. Sinha brought experience at companies including Alexion, ElevateBio and Scholar Rock. Bresge highlighted the financial and strategic guidance he could provide. The appointment followed the Series B, placing another experienced finance executive in the organization’s governance structure.
Bresge also serves on Ray’s board. Around him, the company has built leadership covering development, research, manufacturing, quality, finance and corporate affairs. That distribution of responsibilities puts some substance behind the phrase “company building.” A founder’s work changes as the company grows. More decisions involve specialists, and the organization needs ways to connect their judgments.
At the other end of the pitch
Alongside his company roles, Bresge became an outside director of Healios in 2022. He is also a mentor in the Winning Pitch Challenge. These activities place him in conversations beyond his own executive team, where experience can be useful to another organization or to someone still working out how to present an idea.
Healios’s nomination of Bresge described experience in raising capital, creating shareholder value and completing transactions. The board role therefore drew on responsibilities he had already carried elsewhere. It also extended the international side of a career that included the Santen agreement. His work at Ray and his outside directorship are separate roles, joined by experience in launching and running organizations.
Mentoring adds a smaller-scale encounter to that picture. A pitch asks someone to make an idea understandable to people who have other demands on their attention. Bresge has spent years on the executive side of that exchange. His involvement with the Winning Pitch Challenge puts him alongside founders making their own case, with the experience of having needed partners himself.
He has taken part in public business discussions, too. An OIS panel released as podcast episode 388 brought him together with Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, moderated by Beth Marsh. The subjects included early commercial strategy, institutional funding and how plans evolve. It is a fitting conversation for someone whose own career has required several revisions of the plan.
The record now includes a courier business, an industrial tool company, years at jCyte and a second startup with an expanding group of backers. Bresge’s path keeps returning to practical questions about people and partnerships. Starting again gave those questions a new company to work on. The experience came with him.